Cialis Research Studies
On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction.
Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells.
IC351 (tadalafil, Cialis): update on clinical experience.
Tadalafil (Cialis) for men with erectile dysfunction.
Pharmacology of phosphodiesterase-5 inhibitors.
Phosphodiesterase 5 inhibitors: current status and potential applications.
Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.
Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction.
Effects of tadalafil on erectile dysfunction in men with diabetes.
Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
Pharmacological management of erectile dysfunction.
Tadalafil Lilly ICOS.
Tadalafil: a new agent for erectile dysfunction.
[How effective are PDE-5 inhibitors?]
PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.
Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial.
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.
Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
Tadalafil.
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1@apos;,5@apos;:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1@apos;,2@apos;:1,6]pyrido[3,4-b]indole-1,4-dione analogues.
Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey.
Cialis (tadalafil): a new treatment for erectile dysfunction.
Review of tadalafil in the treatment of erectile dysfunction.
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
Cardiovascular effects of tadalafil.
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
Tadalafil in the treatment of erectile dysfunction.
Time course of the interaction between tadalafil and nitrates.
Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
[Pleasure and pain in sexual relations. The basis and reasons for sex counseling by the general practitioner]
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.
Nocturnal electrobioimpedance volumetric assessment in diabetic men with erectile dysfunction before and after tadalafil intake.
Treatment of erectile dysfunction.
Emerging oral drugs for erectile dysfunction.
The efficacy and safety of tadalafil: an update.
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Potency, selectivity, and consequences of nonselectivity of PDE inhibition.
The efficacy and safety of tadalafil in United States and Puerto Rican men with erectile dysfunction.
New oral drugs for erectile dysfunction.
Time/duration effectiveness of sildenafil versus tadalafil in the treatment of erectile dysfunction in male spinal cord-injured patients.
Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction.
Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial.
Population dose-response model for tadalafil in the treatment of male erectile dysfunction.
Structure elucidation of sildenafil analogues in herbal products.
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction.
New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Discrimination of normal and dyskaryotic cells with a new high-resolution system (CIALIS).